Poland· PL-100470631
Carvykti
A ciltacabtagene autoleucel product containing ciltacabtagenum autoleucelum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ciltacabtagene autoleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL05 (ciltacabtagene autoleucel), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Ciltacabtagene autoleucel · ATC L01XL05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Ciltacabtagenum autoleucelum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L01XL05
- ATC class
- Ciltacabtagene autoleucel
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05413868121568
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ciltacabtagene autoleucel in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCARVYKTIJanssen Biotech, Inc.
- SwitzerlandCarvyktiJanssen-Cilag AG
- CzechiaCARVYKTIJanssen-Cilag International N.V., Beerse
- SpainCARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSIONJanssen-Cilag International N.V
- FinlandCARVYKTIJanssen-Cilag International NV
- FranceCARVYKTI 3,2 x 1 000 000 - 1 x 100 000 000 cellules, dispersion pour perfusionJANSSEN CILAG INTERNATIONAL NV
- BelgiumCarvykti 3,2 x 10*6-1,0 x 10*8 cellsJanssen-Cilag International
- IrelandCARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen Pharmaceutica NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Carvykti
- Liechtenstein · Carvykti
- Norway · Carvykti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c1724dfa-c9d5-4e33-91cc-9118324e622a GET /v1/drugs/c1724dfa-c9d5-4e33-91cc-9118324e622a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dyspersja do infuzji",
"source": "urpl",
"strength": "3,2 × 10^6 - 1,0 × 10^8 komórek",
"packaging": "05413868121568 ¦ Rpz ¦ EU/1/22/1648/001 ¦ 145613\n1 worek 30 ml lub 70 ml",
"substance": "Ciltacabtagenum autoleucelum 3,2 × 10^6 - 1,0 × 10^8 komórek",
"common_name": "Ciltacabtagenum autoleucelum",
"pl_product_id": "100470631",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ciltacabtagene autoleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.